Recombinant human FGF 23 protein (ab108553)



  • 由来
  • 由来
    HEK 293 cells
  • アミノ酸配列
    • アクセッション番号
    • 生物種
    • 分子量
      60 kDa including tags
    • 領域
      1 to 251



Our Abpromise guarantee covers the use of ab108553 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • 生理活性
    Activates ERK and FRS2alpha phosphorylation in Klotho expressing cells.
  • アプリケーション

    Functional Studies


  • エンドトキシン・レベル
    < 0.100 Eu/µg
  • 精製度
    > 90 % SDS-PAGE.
    ab108553 is 0.2µm filtered.
  • 製品の状態
  • 備考
    Working aliquots are stable for up to 3 months when stored at -20°C.
  • Concentration information loading...


  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: PBS

    This product is an active protein and may elicit a biological response in vivo, handle with caution.


  • 別名
    • ADHR
    • FGF-23
    • Fgf23
    • FGF23_HUMAN
    • FGFN
    • Fibroblast growth factor 23
    • Fibroblast growth factor 23 C-terminal peptide
    • Fibroblast growth factor 23 precursor
    • HPDR2
    • HYPF
    • Phosphatonin
    • PHPTC
    • Tumor derived hypophosphatemia inducing factor
    • Tumor-derived hypophosphatemia-inducing factor
    see all
  • 機能
    Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.
  • 組織特異性
    Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).
  • 関連疾患
    Defects in FGF23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR) [MIM:193100]. ADHR is characterized by low serum phosphorus concentrations, rickets, osteomalacia, leg deformities, short stature, bone pain and dental abscesses.
    Defects in FGF23 are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC) [MIM:211900]. HFTC is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues.
  • 配列類似性
    Belongs to the heparin-binding growth factors family.
  • 翻訳後修飾
    Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases.
    O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.
  • 細胞内局在
    Secreted. Secretion is dependent on O-glycosylation.
  • Information by UniProt

Recombinant human FGF 23 protein 画像

  • ERK and FRS2aplha phosphorylation induced by FGF 23 in Klotho expressing cells.
    Klotho expressing HEK 293EBNA cells were serum starved for 16hr and then stimulated with hFGF 23-His, FGF 23-Fc (ab108553), mCD137-Fc (Fc control) and FGF-b (positive control) for 10 min, respectively.
    Antibodies against pFRS2alpha, pERK1/2 & total ERK1/2 were used for immunoblotting.

    Lane 1: Mock (non-treated)
    Lane 2: Mock + hFGF 23-Fc (ab108553) 1µg/ml
    Lane 3: Mock + hFGF 23-His 1µg/ml
    Lane 4: Klotho + hFGF 23-Fc (ab108553) 1µg/ml
    Lane 5: Klotho + hFGF 23-Fc (ab108553) 4µg/ml
    Lane 6: Klotho + mCD137-Fc 1µg/ml
    Lane 7: Klotho (non-treated)
    Lane 8: Klotho + 100ng/ml FGF-b

Recombinant human FGF 23 protein (ab108553) 使用論文

ab108553 has not yet been referenced specifically in any publications.

Product Wall

Sorry for the delay in getting back to you. Unfortunately in investigating your case further I have identified that the vial you have been sent may not be of the expected product. I am looking into exactly why this has happened and how this can be ...

Read More

Thank you for contacting us and reporting the inconsistency in information provided from the concentration to the volume received. I have contacted the source of this protein to check all the details and will let you know as soon as I have any fur...

Read More